Elanco Animal Health (ELAN) Scheduled to Post Earnings on Thursday

Elanco Animal Health (NYSE:ELAN) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.12 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 EPS. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $12.67 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The stock’s 50 day simple moving average is $14.07 and its 200-day simple moving average is $14.73. The company has a market cap of $6.26 billion, a PE ratio of -4.98, a price-to-earnings-growth ratio of 1.32 and a beta of 1.41. Elanco Animal Health has a 1-year low of $9.26 and a 1-year high of $18.80.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays dropped their price target on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.00.

Insider Buying and Selling

In other news, Director Michael J. Harrington bought 3,500 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average cost of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.